Compare Kaltura Inc (KLTR) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kaltura Inc vs Novo Nordisk A/S — how do they compare? Kaltura Inc trades at $1.32 (market cap $199.08M), while Novo Nordisk A/S trades at $38.6 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 830.4× Kaltura Inc's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Kaltura Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kaltura Inc for 21 Days and Novo Nordisk A/S for 116 Days on average.
| KLTR | NVO | |
|---|---|---|
Market Cap | $199.08M | $165.31B |
Volume | 175,927 | 11,432,838 |
Sector | Technology | Health |
52-Week High | $1.89 | $63.98 |
52-Week Low | $1.08 | $35.29 |
Typical Hold Time | 21 Days | 116 Days |
Enterprise Value | $211.29M | $179.56B |
Dividend Yield | — | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KLTR trades at $1.32, down 0.75% on the day, with bearish technical signals from moving averages. The company shows improving fundamentals with revenue stabilizing around $181M and narrowing losses, though it remains unprofitable with negative ROE. Recent analyst coverage leans positive with 44% buy ratings, supported by multiple industry awards and AI platform deployments in 2026.
The outlook remains speculative given persistent losses and high valuation ratios, but growing AI integration and award recognition provide catalysts. Key risks include cash burn, competitive pressure, and execution challenges in achieving profitability. Wall Street sentiment is cautiously optimistic despite technical weakness.
Novo Nordisk (NVO) trades at $38.64, up 0.99% with bearish technical signals despite strong fundamentals. The company maintains exceptional profitability with 35.35% net margins and has beaten earnings estimates for three consecutive quarters. Recent news highlights pipeline developments including weight-loss drug advancements and a $4 billion licensing deal expansion.
While facing competitive pressure in obesity treatments, NVO's valuation remains attractive with a 9.66 P/E ratio. Analyst consensus is bullish with a $44.67 price target, representing 15.6% upside potential. Key risks include FDA regulatory delays and intensifying competition from Eli Lilly in the GLP-1 market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kaltura Inc
Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments: (i) Enterprise, Education, and Technology (EE&T)
Read more on KLTR →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
